|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
GB9710809D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
GB9710807D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
US6140081A
(en)
|
1998-10-16 |
2000-10-31 |
The Scripps Research Institute |
Zinc finger binding domains for GNN
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US6453242B1
(en)
|
1999-01-12 |
2002-09-17 |
Sangamo Biosciences, Inc. |
Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
|
|
HK1043608B
(en)
|
1999-08-17 |
2007-12-07 |
Biogen Ma Inc. |
Baff receptor (bcma), an immunoregulatory agent
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
HK1052372A1
(zh)
|
2000-02-24 |
2003-09-11 |
Xcyte Therapies, Inc. |
细胞的同步刺激和富集
|
|
JP2002060786A
(ja)
|
2000-08-23 |
2002-02-26 |
Kao Corp |
硬質表面用殺菌防汚剤
|
|
US7446179B2
(en)
|
2000-11-07 |
2008-11-04 |
City Of Hope |
CD19-specific chimeric T cell receptor
|
|
AU2002238052A1
(en)
|
2001-02-20 |
2002-09-04 |
Zymogenetics, Inc. |
Antibodies that bind both bcma and taci
|
|
US20040224385A1
(en)
|
2001-08-20 |
2004-11-11 |
Barbas Carlos F |
Zinc finger binding domains for cnn
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
US20080025989A1
(en)
|
2003-02-20 |
2008-01-31 |
Seattle Genetics, Inc. |
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
|
US7662387B2
(en)
|
2003-02-20 |
2010-02-16 |
Seattle Genetics |
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
|
EP1460088A1
(en)
|
2003-03-21 |
2004-09-22 |
Biotest AG |
Humanized anti-CD4 antibody with immunosuppressive properties
|
|
DE10328289B3
(de)
|
2003-06-23 |
2005-01-05 |
Enginion Ag |
Arbeitsmedium für Dampfkreisprozesse
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US7641903B2
(en)
|
2004-10-15 |
2010-01-05 |
Seattle Genetics, Inc. |
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
|
US20120294863A1
(en)
|
2004-10-15 |
2012-11-22 |
Seattle Genetics, Inc. |
Anti-CD70 Antibody and Its Use for the Treatment and Prevention of Cancer and Immune Disorders
|
|
US8337838B2
(en)
|
2004-10-15 |
2012-12-25 |
Seattle Genetics, Inc. |
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
|
WO2006044643A2
(en)
|
2004-10-15 |
2006-04-27 |
Seattle Genetics, Inc. |
Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
|
EP3530321A1
(en)
|
2004-12-10 |
2019-08-28 |
Peter MacCallum Cancer Institute |
Methods and compositions for adoptive immunotherapy
|
|
US8067546B2
(en)
|
2005-04-19 |
2011-11-29 |
Seattle Genetics, Inc. |
Humanized anti-CD70 binding agents and uses thereof
|
|
CN103145837A
(zh)
|
2005-06-30 |
2013-06-12 |
Abbvie公司 |
Il-12/p40结合蛋白
|
|
EP1934261B1
(en)
|
2005-09-26 |
2014-10-29 |
Medarex, L.L.C. |
Human monoclonal antibodies to cd70
|
|
US20100150950A1
(en)
*
|
2006-12-14 |
2010-06-17 |
Medarex, Inc. |
Human antibodies that bind cd70 and uses thereof
|
|
US8389282B2
(en)
|
2007-03-30 |
2013-03-05 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
|
|
US7771720B2
(en)
|
2007-09-07 |
2010-08-10 |
Cisthera, Inc. |
Humanized PAI-1 antibodies
|
|
ES2588194T3
(es)
|
2008-04-11 |
2016-10-31 |
Seattle Genetics, Inc. |
Detección y tratamiento de cáncer pancreático, de ovario y otros cánceres
|
|
CA2729567C
(en)
|
2008-06-30 |
2018-04-24 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-cd27 antibody
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
PT2816112T
(pt)
|
2009-12-10 |
2018-11-20 |
Univ Iowa State Res Found Inc |
Modificação do adn modificada pelo efector tal
|
|
AU2010339359A1
(en)
|
2009-12-29 |
2012-07-26 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-CD27 antibody
|
|
US8993524B2
(en)
|
2010-03-05 |
2015-03-31 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
US20120213771A1
(en)
|
2010-04-13 |
2012-08-23 |
Celldex Therapeutics Inc. |
Antibodies that bind human cd27 and uses thereof
|
|
JP6002659B2
(ja)
|
2010-04-13 |
2016-10-05 |
セルデックス・セラピューティクス・インコーポレイテッド |
ヒトｃｄ２７に結合する抗体およびその使用
|
|
CA2804550C
(en)
|
2010-07-09 |
2021-01-05 |
Bionovion Holding B.V. |
Agonistic antibody to cd27
|
|
CA2816379A1
(en)
*
|
2010-10-27 |
2012-05-03 |
Baylor College Of Medicine |
Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
BR112013021562B1
(pt)
|
2011-03-16 |
2023-01-10 |
Argenx Bvba |
Anticorpos para cd70
|
|
EP2714737A1
(en)
|
2011-05-27 |
2014-04-09 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) -binding proteins
|
|
US9382319B2
(en)
|
2011-09-26 |
2016-07-05 |
Jn Biosciences Llc |
Hybrid constant regions
|
|
SG11201401699WA
(en)
|
2011-11-11 |
2014-09-26 |
Rinat Neuroscience Corp |
Antibodies specific for trop-2 and their uses
|
|
WO2013074916A1
(en)
|
2011-11-18 |
2013-05-23 |
Board Of Regents, The University Of Texas System |
Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
|
|
KR20130060720A
(ko)
|
2011-11-30 |
2013-06-10 |
한국전자통신연구원 |
목적 기반 시맨틱 서비스 디스커버리를 위한 서비스 목적 해석 장치 및 방법
|
|
JO3787B1
(ar)
|
2012-03-15 |
2021-01-31 |
Janssen Biotech Inc |
أجسام مضادة بشرية ضد cd27 و طرق و استخداماتها
|
|
AU2013246443B2
(en)
|
2012-04-11 |
2017-04-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting B-cell maturation antigen
|
|
SG10201806573TA
(en)
|
2012-05-25 |
2018-09-27 |
Cellectis |
Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
|
|
EP2914628A1
(en)
|
2012-11-01 |
2015-09-09 |
Max-Delbrück-Centrum für Molekulare Medizin |
An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
|
|
JP6636803B2
(ja)
|
2013-02-05 |
2020-01-29 |
エンクマフ エスアーエールエル |
Ｂｃｍａに対する抗体の選択のための方法
|
|
WO2014158821A1
(en)
|
2013-03-12 |
2014-10-02 |
Imaginab, Inc. |
Antigen binding constructs to cd70
|
|
HK1220698A1
(zh)
|
2013-03-13 |
2017-05-12 |
Seattle Genetics, Inc. |
环糊精和抗体药物偶联物制剂
|
|
WO2014140374A2
(en)
|
2013-03-15 |
2014-09-18 |
Novo Nordisk A/S |
Monovalent cd27 antibodies
|
|
AU2014235968B2
(en)
|
2013-03-21 |
2018-05-24 |
Ospedale San Raffaele Srl |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
EP4286517A3
(en)
|
2013-04-04 |
2024-03-13 |
President and Fellows of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
|
JP6608807B2
(ja)
|
2013-05-29 |
2019-11-20 |
セレクティス |
Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法
|
|
CN111218447B
(zh)
|
2013-11-07 |
2024-10-11 |
爱迪塔斯医药有限公司 |
使用统治型gRNA的CRISPR相关方法和组合物
|
|
EP3858379A1
(en)
|
2013-11-21 |
2021-08-04 |
Autolus Limited |
Cell
|
|
KR20240164967A
(ko)
|
2014-02-04 |
2024-11-21 |
카이트 파마 인코포레이티드 |
B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법
|
|
DK3105317T3
(en)
|
2014-02-14 |
2019-01-14 |
Cellectis |
Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
|
|
EP3114217A4
(en)
|
2014-03-07 |
2017-09-20 |
Bellicum Pharmaceuticals, Inc. |
Caspase polypeptides having modified activity and uses thereof
|
|
RU2752933C2
(ru)
*
|
2014-03-11 |
2021-08-11 |
Селлектис |
Способ создания т-клеток, пригодных для аллогенной трансплантации
|
|
CN122399016A
(zh)
|
2014-03-15 |
2026-07-17 |
诺华股份有限公司 |
使用嵌合抗原受体治疗癌症
|
|
EP3131927B8
(en)
|
2014-04-14 |
2020-12-23 |
Cellectis |
Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
|
|
SG11201608701QA
(en)
*
|
2014-04-18 |
2016-11-29 |
Editas Medicine Inc |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
|
US20170158749A1
(en)
|
2014-04-23 |
2017-06-08 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) and methods for making and using the same
|
|
ES2836743T3
(es)
|
2014-06-02 |
2021-06-28 |
Us Health |
Receptores de antígeno quiméricos que seleccionan como diana CD-19
|
|
US9970001B2
(en)
|
2014-06-05 |
2018-05-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease design
|
|
AU2015292744C1
(en)
|
2014-07-21 |
2021-01-21 |
Novartis Ag |
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
|
|
EP3172231B1
(en)
|
2014-07-24 |
2021-05-05 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors
|
|
RU2017102769A
(ru)
|
2014-07-29 |
2018-08-28 |
Пфайзер Инк. |
EGFRvIII СПЕЦИФИЧЕСКИЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ ДЛЯ ИММУНОТЕРАПИИ РАКА
|
|
CA2957929A1
(en)
|
2014-08-12 |
2016-02-18 |
Anthrogenesis Corporation |
Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
|
|
GB201418965D0
(enExample)
|
2014-10-24 |
2014-12-10 |
Ospedale San Raffaele And Fond Telethon |
|
|
KR102546296B1
(ko)
*
|
2014-10-31 |
2023-06-21 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
|
|
WO2016073955A2
(en)
|
2014-11-06 |
2016-05-12 |
President And Fellows Of Harvard College |
Cells lacking b2m surface expression and methods for allogeneic administration of such cells
|
|
CA2969619A1
(en)
|
2014-12-03 |
2016-06-09 |
Agilent Technologies, Inc. |
Guide rna with chemical modifications
|
|
CN113698497A
(zh)
|
2014-12-05 |
2021-11-26 |
纪念斯隆-凯特琳癌症中心 |
靶向b-细胞成熟抗原的嵌合抗原受体及其用途
|
|
EP3230310B1
(en)
*
|
2014-12-08 |
2019-06-12 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Anti-cd70 chimeric antigen receptors
|
|
US10383929B2
(en)
|
2014-12-12 |
2019-08-20 |
Bluebird Bio, Inc. |
BCMA chimeric antigen receptors
|
|
RU2017125531A
(ru)
|
2014-12-19 |
2019-01-21 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Химерные антигенные рецепторы и способы их применения
|
|
EP3250602A1
(en)
|
2015-01-26 |
2017-12-06 |
Cellectis |
T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
|
|
GB201504840D0
(en)
|
2015-03-23 |
2015-05-06 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
BR112017020750A2
(en)
|
2015-03-27 |
2018-06-26 |
President And Fellows Of Harvard College |
modified t-cells and methods of producing and using them
|
|
CN107787367B
(zh)
|
2015-04-06 |
2021-10-26 |
里兰斯坦福初级大学理事会 |
用于crispr/cas介导的基因调控的化学修饰的引导rna
|
|
US20190031759A1
(en)
|
2015-04-30 |
2019-01-31 |
Technion Research & Development Foundation Limited |
Chimeric antigen receptors and methods of their use
|
|
EP3294342A4
(en)
|
2015-05-08 |
2018-11-07 |
President and Fellows of Harvard College |
Universal donor stem cells and related methods
|
|
EP3770168A1
(en)
|
2015-05-18 |
2021-01-27 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
CN104910278B
(zh)
|
2015-05-27 |
2018-05-25 |
上海吉凯基因科技有限公司 |
一种用于制备cart细胞的具有高效转染能力和生物学活性的慢病毒
|
|
EP4339287A3
(en)
|
2015-07-31 |
2024-05-22 |
Regents Of The University Of Minnesota |
Modified cells and methods of therapy
|
|
EP3858388B1
(en)
|
2015-09-28 |
2024-07-03 |
Regents of the University of Minnesota |
Chimeric antigen receptor (car) t cells as therapeutic interventions for gvhd
|
|
ES2803728T3
(es)
|
2015-10-05 |
2021-01-29 |
Prec Biosciences Inc |
Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado
|
|
GB201518136D0
(en)
|
2015-10-14 |
2015-11-25 |
Glaxosmithkline Ip Dev Ltd |
Novel chimeric antigen receptors
|
|
WO2017070429A1
(en)
|
2015-10-22 |
2017-04-27 |
Regents Of The University Of Minnesota |
Methods involving editing polynucleotides that encode t cell receptor
|
|
WO2017075537A1
(en)
|
2015-10-30 |
2017-05-04 |
Aleta Biotherapeutics Inc. |
Compositions and methods for treatment of cancer
|
|
JP6901493B2
(ja)
|
2015-11-13 |
2021-07-14 |
アメリカ合衆国 |
抗ｂｃｍａポリペプチド及びタンパク質
|
|
WO2017093969A1
(en)
|
2015-12-04 |
2017-06-08 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
US11052111B2
(en)
|
2015-12-08 |
2021-07-06 |
Chimera Bioengineering, Inc. |
Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
|
|
AU2016374253B2
(en)
|
2015-12-18 |
2021-10-21 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the MHC cell receptor
|
|
US11352631B2
(en)
|
2015-12-18 |
2022-06-07 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
|
US20190017075A1
(en)
|
2015-12-23 |
2019-01-17 |
Precision Biosciences, Inc. |
Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene
|
|
ITUB20160112A1
(it)
|
2016-01-28 |
2016-04-28 |
Serteaweb Srl |
Processo di allarme e sistema televisivo relativo ad un tale processo di allarme
|
|
MA44254A
(fr)
|
2016-02-17 |
2018-12-26 |
Seattle Genetics Inc |
Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques
|
|
SG11201807489PA
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
US20190241910A1
(en)
|
2016-03-11 |
2019-08-08 |
Bluebird Bio, Inc. |
Genome edited immune effector cells
|
|
KR102427334B1
(ko)
|
2016-04-01 |
2022-08-03 |
카이트 파마 인코포레이티드 |
키메라 항원 및 t 세포 수용체 및 사용 방법
|
|
CN113082201B
(zh)
|
2016-04-01 |
2024-07-05 |
上海斯丹赛生物技术有限公司 |
刺激t细胞介导的对表达抗原的细胞群的免疫应答的方法
|
|
AU2017248259A1
(en)
|
2016-04-07 |
2018-10-25 |
Bluebird Bio, Inc. |
Chimeric antigen receptor T cell compositions
|
|
CA3020993A1
(en)
|
2016-04-14 |
2017-10-19 |
Bluebird Bio, Inc. |
Salvage chimeric antigen receptor systems
|
|
EP3445378A1
(en)
|
2016-04-22 |
2019-02-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and vaccine compositions for the treatment of b-cell malignancies
|
|
US11141471B2
(en)
|
2016-04-25 |
2021-10-12 |
Regen BioPharma, Inc. |
Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells
|
|
US10875919B2
(en)
|
2016-04-26 |
2020-12-29 |
Alector Llc |
Chimeric receptors and methods of use thereof
|
|
US11596699B2
(en)
|
2016-04-29 |
2023-03-07 |
CureVac SE |
RNA encoding an antibody
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
EP3452499A2
(en)
|
2016-05-06 |
2019-03-13 |
Juno Therapeutics, Inc. |
Genetically engineered cells and methods of making the same
|
|
WO2017210617A2
(en)
|
2016-06-02 |
2017-12-07 |
Porter, David, L. |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
US12048718B2
(en)
|
2016-06-07 |
2024-07-30 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft |
Chimeric antigen receptor and CAR-T cells that bind BCMA
|
|
CN109562126A
(zh)
|
2016-06-24 |
2019-04-02 |
美商生物细胞基因治疗有限公司 |
嵌合抗原受体(car)、组合物及其使用方法
|
|
CN106544321B
(zh)
|
2016-10-13 |
2019-01-29 |
北京艺妙神州医疗科技有限公司 |
通用型car-t细胞及其制备方法和用途
|
|
WO2018068257A1
(zh)
|
2016-10-13 |
2018-04-19 |
北京艺妙神州医疗科技有限公司 |
通用型car-t细胞及其制备方法和用途
|
|
WO2018073393A2
(en)
*
|
2016-10-19 |
2018-04-26 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
|
WO2018073391A1
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Targeted gene insertion for improved immune cells therapy
|
|
AU2018208614A1
(en)
|
2017-01-10 |
2019-07-11 |
The General Hospital Corporation |
Modified T cells and methods of their use
|
|
BR112019023608A2
(pt)
*
|
2017-05-12 |
2020-05-26 |
Crispr Therapeutics Ag |
Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
|
|
WO2019119036A1
(en)
*
|
2017-12-19 |
2019-06-27 |
Benitec Biopharma Limited |
Cd70 deficient cells, and methods and reagents for producing same
|
|
MX2020008184A
(es)
|
2018-02-01 |
2020-09-22 |
Pfizer |
Receptores de antigeno quimericos dirigidos a cd70.
|
|
US11957695B2
(en)
*
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|